

with P-gp substrates/inhibitors in controlled studies. Renal function is the only important factor affecting lenalidomide plasma exposure, and the starting dose needs to be adjusted based on the creatinine clearance value (<60 mL/min). Age (39 to 85 years), body weight (33 to 135 kg), sex, race, and type of hematological malignancies (MM, MDS, or MCL) did not have a clinically relevant effect on lenalidomide clearance in adult subjects.

[0012] A phase 2/3 randomized, NCCN-listed study of lenalidomide monotherapy vs chemotherapy was conducted in subjects with R/R DLBCL. Lenalidomide-treated subjects had an objective response rate (ORR) of 27.5% as compared with 11.8% in investigator's choice chemotherapy (ORR were similar regardless of immunohistochemistry [IHC]-defined DLBCL subtype). Median progression-free survival (PFS) was increased in subjects receiving lenalidomide (13.6 weeks) versus investigator's choice (7.9 weeks; P=0.041), with greater improvements in non-germinal-center B-cell-like (GCB) subjects (15.1 vs 7.1 weeks, respectively; P=0.021) compared with GCB (10.1 vs 9.0 weeks, respectively; P=0.550).

[0013] Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Rituximab is marketed in the US and the European Union (EU) for use in combination chemotherapy for previously untreated NHL, including indolent B-cell lymphomas and DLBCL; it is also approved for chronic lymphocytic leukemia (CLL) and other diseases

SUMMARY

[0014] In one aspect, the present disclosure provides a use of an antibody-drug conjugate that binds to CD30 in the manufacture of a medicament for use in combinatorial therapy for treating non-Hodgkin lymphoma in a subject, wherein said medicament is to be administered to the subject in combination with lenalidomide, or salt or solvate thereof, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

[0014a] In another aspect, the present disclosure provides a use of an antibody-drug conjugate that binds to CD30 and lenalidomide, or salt or solvate thereof in the manufacture of a

medicament for combination therapy to treat non-Hodgkin lymphoma in a subject, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

[0014b] In another aspect, the present disclosure provides a use of an antibody-drug conjugate that binds to CD30 in the manufacture of a first medicament and use of lenalidomide, or salt or solvate thereof in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat non-Hodgkin lymphoma in a subject, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

[0014c] Provided herein is a method of treating non-Hodgkin lymphoma in a subject, the method comprising administering to the subject lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof. In some embodimentexamples, the non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). In some embodimentexamples, the DLBCL is relapsed DLBCL. In some embodimentexamples, the DLBCL is refractory DLBCL. In some embodimentexamples, the DLBCL is germinal-center B-cell like (GCB). In some embodimentexamples, the

DLBCL is non-GCB. In some [embodimentexamples](#), the subject has previously received allogenic stem cell transplant to treat the non-Hodgkin lymphoma. In some [embodimentexamples](#), the subject has previously received autologous stem cell transplant to treat the non-Hodgkin lymphoma. In some [embodimentexamples](#), the subject relapsed following stem cell transplant. In some [embodimentexamples](#), the subject has previously received CAR-T therapy. In some [embodimentexamples](#), the subject relapsed after CAR-T therapy. In some [embodimentexamples](#), the subject has not been previously treated with lenalidomide, or salt or solvate thereof. In some [embodimentexamples](#), the subject has not been previously treated with an antibody-drug conjugate that binds to CD30. In some [embodimentexamples](#), the non-Hodgkin lymphoma is an advanced stage non-Hodgkin lymphoma. In some [embodimentexamples](#), the advanced stage non-Hodgkin lymphoma is a stage 3 or stage 4 non-Hodgkin lymphoma. In some [embodimentexamples](#), the advanced stage non-Hodgkin lymphoma is metastatic non-Hodgkin lymphoma. In some [embodimentexamples](#), the non-Hodgkin lymphoma is recurrent non-Hodgkin lymphoma. In some [embodimentexamples](#), at least 1% of the non-Hodgkin lymphoma cells in the subject express CD30. In some [embodimentexamples](#), the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:

- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and


wherein the light chain variable region comprises:

- (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
- (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
- (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some

[embodimentexamples](#), the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 8. In some [embodimentexamples](#), the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8. In some [embodimentexamples](#), the anti-CD30 antibody of


the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8. In some [embodimentexamples](#), the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. In some [embodimentexamples](#), the anti-CD30 antibody is AC10. In some [embodimentexamples](#), the anti-CD30 antibody is cAC10. In some [embodimentexamples](#), the antibody-drug conjugate further comprises a linker between the anti-CD30 antibody or antigen-binding portion thereof and the monomethyl auristatin. In some [embodimentexamples](#), the linker is a cleavable peptide linker. In some [embodimentexamples](#), the cleavable peptide linker has a formula: -MC-vc-PAB-, wherein:

a) MC is:



b) vc is the dipeptide valine-citrulline, and

c) PAB is:



. In some [embodimentexamples](#), the monomethyl auristatin is monomethyl auristatin E (MMAE). In some [embodimentexamples](#), the monomethyl auristatin is monomethyl auristatin F (MMAF). In some [embodimentexamples](#), the antibody-drug conjugate is brentuximab vedotin or a biosimilar thereof. In some [embodimentexamples](#), wherein the antibody-drug conjugate is brentuximab vedotin. In some [embodimentexamples](#), the lenalidomide, or salt or solvate

thereof, is administered at a dose of 1 to 30 mg. In some [embodimentexamples](#), the lenalidomide, or salt or solvate thereof, is administered at a dose of 20 mg. In some [embodimentexamples](#), the lenalidomide, or salt or solvate thereof, is administered orally. In some [embodimentexamples](#), the lenalidomide, or salt or solvate thereof, is administered about once per day. In some [embodimentexamples](#), the antibody-drug conjugate is administered at a dose of 0.6 mg/kg to 2.3 mg/kg of the subject's bodyweight. In some [embodimentexamples](#), the antibody-drug conjugate is administered at a dose of about 0.9 mg/kg of the subject's bodyweight. In some [embodimentexamples](#), the antibody-drug conjugate is administered at a dose of 0.9 mg/kg of the subject's bodyweight. In some [embodimentexamples](#), the antibody-drug conjugate is administered at a dose of about 1.2 mg/kg of the subject's bodyweight. In some [embodimentexamples](#), the antibody-drug conjugate is administered at a dose of 1.2 mg/kg of the subject's bodyweight. In some [embodimentexamples](#), the antibody-drug conjugate is administered to subjects having a bodyweight of greater than 100 kg as if the subject had a bodyweight of 100 kg. In some [embodimentexamples](#), the antibody-drug conjugate is administered to the subject once about every 3 weeks. In some [embodimentexamples](#), the antibody-drug conjugate is administered to the subject once every 3 weeks. In some [embodimentexamples](#), the antibody-drug conjugate is administered to the subject on about day 1 of about a 21-day treatment cycle. In some [embodimentexamples](#), the antibody-drug conjugate is administered to the subject on day 1 of a 21-day treatment cycle. In some [embodimentexamples](#), the antibody-drug conjugate is administered by intravenous infusion. In some [embodimentexamples](#), the method further comprises the administration of an anti-CD20 antibody or antigen-binding fragment thereof to the subject. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the three CDRs of SEQ ID NO:17, a light chain variable region comprising the three CDRs of SEQ ID NO:18, wherein the CDRs of the anti-CD20 antibody are defined by the Kabat numbering scheme. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:17 and a light chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:18. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is rituximab or a

biosimilar thereof. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is rituximab. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of 100 mg/m² to 500 mg/m² of the subject's body surface area. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of about 375 mg/m² of the subject's body surface area. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of 375 mg/m² of the subject's body surface area. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of 500 mg to 2000 mg. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of about 1400 mg. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of 1400 mg. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered to the subject once about every 3 weeks. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered to the subject once every 3 weeks. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered to the subject on about day 1 of about a 21-day treatment cycle. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered to the subject on day 1 of a 21-day treatment cycle. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered by intravenous infusion. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered by subcutaneous injection. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of about 375 mg/m² of the subject's body surface area by intravenous infusion on about day 1 of the first 21-day treatment cycle and is administered at a dose of about 1400 mg by subcutaneous injection on about day 1 of each 21-day treatment cycle thereafter. In some [embodimentexamples](#), the anti-CD20 antibody or antigen-binding fragment thereof is administered at a dose of 375 mg/m² of the subject's body surface area by intravenous infusion on day 1 of the first 21-day treatment cycle and is administered at a dose of 1400 mg by subcutaneous injection on day 1 of each 21-day treatment cycle thereafter. In some [embodimentexamples](#), the method further comprises the administration of granulocyte-colony stimulating factor (G-CSF) to the subject. In some [embodimentexamples](#), the G-CSF is administered 1 to 3 days after the administration of the anti-CD30 antibody-drug conjugate. In some [embodimentexamples](#), the G-CSF is selected from the group consisting of filgrastim, PEG-

filgrastim, lenograstim, and tbo-filgrastim. In some [embodimentexamples](#), administering the lenalidomide, or salt or solvate thereof, and the antibody-drug conjugate that binds to CD30 to the subject results in a depletion of cancer cells by at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% compared to the amount of cancer cells before administering the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30 to the subject. In some [embodimentexamples](#), one or more therapeutic effects in the subject is improved after administration of the lenalidomide, or salt or solvate thereof, and the antibody-drug conjugate that binds to CD30 relative to a baseline. In some [embodimentexamples](#), the one or more therapeutic effects is selected from the group consisting of: objective response rate, duration of response, time to response, progression free survival and overall survival. In some [embodimentexamples](#), the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In some [embodimentexamples](#), the subject exhibits progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after administration of the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30. In some [embodimentexamples](#), the subject exhibits overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after administration of the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30. In some [embodimentexamples](#), the duration of response to the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30 is at least about 1 month, at least about 2

months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after administration of the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30. In some embodimentexamples, the subject is a human.

[0015] In yet another aspect, the present disclosure provides a pharmaceutical composition for use in the treatment of non-Hodgkin lymphoma in a subject, the composition comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof. Also provided herein is a pharmaceutical composition for the treatment of non-Hodgkin lymphoma in a subject, the composition comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, wherein the composition is for use in a method of any of the embodimentexamples herein. In some embodimentexamples, the pharmaceutical composition further comprises an anti-CD20 antibody or antigen-binding fragment thereof.

[0016] In yet another aspect, the present disclosure provides a kit comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, and instructions for using the kit to treat non-Hodgkin lymphoma in a subject. Also provided herein is a kit comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, and instructions for using the kit in a method of any of the embodimentexamples herein. In some

| ~~embodiment~~examples, the kit further comprises an anti-CD20 antibody or antigen-binding fragment thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] FIG. 1A-1B is a series of graphs showing progression free survival (FIG. 1A) and overall survival (FIG. 1B) of subjects treated with brentuximab vedotin and lenalidomide.

DETAILED DESCRIPTION

I. Definitions

[0018] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of

CLAIMS

What is claimed is:

1. Use of an antibody-drug conjugate that binds to CD30 in the manufacture of a medicament for use in combinatorial therapy for treating non-Hodgkin lymphoma in a subject, wherein said medicament is to be administered to the subject in combination with lenalidomide, or salt or solvate thereof, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

~~12. A method of treating non-Hodgkin lymphoma in a subject, the method comprising administering to the subject lenalidomide, or salt or solvate thereof, and Use of~~ an antibody-drug conjugate that binds to CD30 and lenalidomide, or salt or solvate thereof in the manufacture of a medicament for combination therapy to treat non-Hodgkin lymphoma in a subject, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

3. Use of an antibody-drug conjugate that binds to CD30 in the manufacture of a first medicament and use of lenalidomide, or salt or solvate thereof in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat non-Hodgkin lymphoma in a subject, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof.

~~24. The method~~ use of any one of claims 1-3, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL).

~~35. The use~~ method of claim 24, wherein the DLBCL is relapsed DLBCL.

~~46. The use~~ method of claim 2-4 or 35, wherein the DLBCL is refractory DLBCL.

~~57~~. The ~~use~~method of any one of claims ~~24-46~~, wherein the DLBCL is germinal-center B-cell like (GCB).

~~68~~. The ~~use~~method of any one of claims ~~24-46~~, wherein the DLBCL is non-GCB.

~~79~~. The ~~use~~method of any one of claims 1-~~68~~, wherein the subject has previously received allogenic stem cell transplant to treat the non-Hodgkin lymphoma.

~~810~~. The ~~method~~use of any one of claims 1-~~79~~, wherein the subject has previously received autologous stem cell transplant to treat the non-Hodgkin lymphoma.

~~911~~. The ~~method~~use of claim ~~7-9~~ or claim ~~810~~, wherein the subject relapsed following stem cell transplant.

~~1012~~. The ~~method~~use of any one of claims 1-~~911~~, wherein the subject has previously received CAR-T therapy.

~~1113~~. The ~~method~~use of claim ~~1012~~, wherein the subject relapsed after CAR-T therapy.

~~1214~~. The ~~method~~use of any one of claims 1-~~1113~~, wherein the subject has not been previously treated with lenalidomide, or salt or solvate thereof.

~~1315~~. The ~~use~~method of any one of claims 1-~~1214~~, wherein the subject has not been previously treated with an antibody-drug conjugate that binds to CD30.

~~1416~~. The ~~use~~method of any one of claims 1-~~1315~~, wherein the non-Hodgkin lymphoma is an advanced stage non-Hodgkin lymphoma.

~~1517~~. The ~~use~~method of claim ~~1416~~, wherein the advanced stage non-Hodgkin lymphoma is a stage 3 or stage 4 non-Hodgkin lymphoma.

~~1618~~. The ~~usemethod~~ of claim ~~14-16~~ or claim ~~1517~~, wherein the advanced stage non-Hodgkin lymphoma is metastatic non-Hodgkin lymphoma.

~~1719~~. The ~~usemethod~~ of any one of claims 1-~~1618~~, wherein the non-Hodgkin lymphoma is recurrent non-Hodgkin lymphoma.

~~1820~~. The ~~usemethod~~ of any one of claims 1-~~1719~~, wherein at least 1% of the non-Hodgkin lymphoma cells in the subject express CD30.

~~1921~~. The ~~usemethod~~ of any one of claims 1-~~1820~~, wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:

- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and

wherein the light chain variable region comprises:

- (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
- (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
- (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

~~2022~~. The ~~usemethod~~ of any one of claims 1-~~1921~~, wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 8.

~~2123~~. The ~~usemethod~~ of any one of claims 1-~~2022~~, wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 8.

2224. The usemethod of any one of claims 1-2123, wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8.

2325. The usemethod of any one of claims 1-1820, wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

2426. The usemethod of any one of claims 1-1820, wherein the anti-CD30 antibody is AC10.


2527. The usemethod of any one of claims 1-1820, wherein the anti-CD30 antibody is cAC10.

2628. The usemethod of any one of claims 1-2527, wherein the antibody-drug conjugate further comprises a linker between the anti-CD30 antibody or antigen-binding portion thereof and the monomethyl auristatin.

2729. The method-use of claim 2628, wherein the linker is a cleavable peptide linker.


2830. The usemethod of claim 2729, wherein the cleavable peptide linker has a formula: -MC-vc-PAB-, wherein:

a) MC is:



b) vc is the dipeptide valine-citrulline, and

c) PAB is:



2931. The usemethod of any one of claims 1-2830, wherein the monomethyl auristatin is monomethyl auristatin E (MMAE).

3032. The usemethod of any one of claims 1-2830, wherein the monomethyl auristatin is monomethyl auristatin F (MMAF).

3133. The usemethod of any one of claims 1-1820, wherein the antibody-drug conjugate is brentuximab vedotin or a biosimilar thereof.

3234. The usemethod of any one of claims 1-1820, wherein the antibody-drug conjugate is brentuximab vedotin.

3335. The usemethod of any one of claims 1-3234, wherein the lenalidomide, or salt or solvate thereof, is to be administered at a dose of 1 to 30 mg.

3436. The usemethod of claim 3335, wherein the lenalidomide, or salt or solvate thereof, is to be administered at a dose of 20 mg.

3537. The usemethod of any one of claims 1-3436, wherein the lenalidomide, or salt or solvate thereof, is to be administered orally.

3638. The usemethod of any one of claims 1-3537, wherein the lenalidomide, or salt or solvate thereof, is to be administered about once per day.

3739. The ~~usemethod~~ of any one of claims 1-3537, wherein the lenalidomide, or salt or solvate thereof, is to be administered once per day.

3840. The ~~usemethod~~ of any one of claims 1-3739, wherein the antibody-drug conjugate is to be administered at a dose of 0.6 mg/kg to 2.3 mg/kg of the subject's bodyweight.

3941. The ~~usemethod~~ of claim 3840, wherein the antibody-drug conjugate is to be administered at a dose of about 0.9 mg/kg of the subject's bodyweight.

4042. The ~~usemethod~~ of claim 3840, wherein the antibody-drug conjugate is to be administered at a dose of 0.9 mg/kg of the subject's bodyweight.

4143. The ~~usemethod~~ of claim 3840, wherein the antibody-drug conjugate is to be administered at a dose of about 1.2 mg/kg of the subject's bodyweight.

4244. The ~~usemethod~~ of claim 3840, wherein the antibody-drug conjugate is to be administered at a dose of 1.2 mg/kg of the subject's bodyweight.

4345. The ~~usemethod~~ of claim 3840, wherein the antibody-drug conjugate is to be administered to subjects having a bodyweight of greater than 100 kg as if the subject had a bodyweight of 100 kg.

4446. The ~~usemethod~~ of any one of claims 1-4345, wherein the antibody-drug conjugate is to be administered to the subject once about every 3 weeks.

4547. The ~~usemethod~~ of any one of claims 1-4345, wherein the antibody-drug conjugate is to be administered to the subject once every 3 weeks.

4648. The ~~usemethod~~ of any one of claims 1-4547, wherein the antibody-drug conjugate is to be administered to the subject on about day 1 of about a 21-day treatment cycle.

4749. The ~~usemethod~~ of any one of claims 1-4547, wherein the antibody-drug conjugate is to be administered to the subject on day 1 of a 21-day treatment cycle.

4850. The ~~usemethod~~ of any one of claims 1-4749, wherein the antibody-drug conjugate is to be administered by intravenous infusion.

4951. The ~~usemethod~~ of any one of claims 1-4850 , wherein the medicament is to be further administered to the subject in combination with~~further comprising the administration of~~ an anti-CD20 antibody or antigen-binding fragment thereof~~to the subject~~.

5052. The ~~usemethod~~ of claim 4951, wherein the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the three CDRs of SEQ ID NO:17, a light chain variable region comprising the three CDRs of SEQ ID NO:18, wherein the CDRs of the anti-CD20 antibody are defined by the Kabat numbering scheme.

5153. The ~~usemethod~~ of claim 49-51 or 5052, wherein the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:17 and a light chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:18.

5254. The ~~usemethod~~ of claim 4951, wherein the anti-CD20 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:18.

5355. The ~~usemethod~~ of claim 4951, wherein the anti-CD20 antibody or antigen-binding fragment thereof is rituximab or a biosimilar thereof.

5456. The ~~usemethod~~ of claim 4951, wherein the anti-CD20 antibody or antigen-binding fragment thereof is rituximab.

5557. The ~~usemethod~~ of any one of claims 4951-5456, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of 100 mg/m² to 500 mg/m² of the subject's body surface area.

5658. The ~~usemethod~~ of claim 5557, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of about 375 mg/m² of the subject's body surface area.

5759. The ~~usemethod~~ of claim 5557, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of 375 mg/m² of the subject's body surface area.

5860. The ~~usemethod~~ of any one of claims 4951-5456, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of 500 mg to 2000 mg.

5961. The ~~usemethod~~ of claim 5860, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of about 1400 mg.

6062. The ~~usemethod~~ of claim 5860, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of 1400 mg.

6163. The ~~usemethod~~ of any one of claims 4951-6062, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered to the subject once about every 3 weeks.

6264. The ~~usemethod~~ of any one of claims 4951-6062, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered to the subject once every 3 weeks.

6365. The ~~usemethod~~ of any one of claims 4951-6264, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered to the subject on about day 1 of about a 21-day treatment cycle.

~~6466~~. The ~~usemethod~~ of any one of claims ~~4951-6264~~, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered to the subject on day 1 of a 21-day treatment cycle.

~~6567~~. The ~~usemethod~~ of any one of claims ~~4951-6466~~, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered by intravenous infusion.

~~6668~~. The ~~usemethod~~ of any one of claims ~~4951-6466~~, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered by subcutaneous injection.

~~6769~~. The ~~usemethod~~ of any one of claims ~~6365-6668~~, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of about 375 mg/m² of the subject's body surface area by intravenous infusion on about day 1 of the first 21-day treatment cycle and is to be administered at a dose of about 1400 mg by subcutaneous injection on about day 1 of each 21-day treatment cycle thereafter.

~~6870~~. The ~~usemethod~~ of any one of claims ~~6365-6668~~, wherein the anti-CD20 antibody or antigen-binding fragment thereof is to be administered at a dose of 375 mg/m² of the subject's body surface area by intravenous infusion on day 1 of the first 21-day treatment cycle and is to be administered at a dose of 1400 mg by subcutaneous injection on day 1 of each 21-day treatment cycle thereafter.

~~6971~~. The ~~usemethod~~ of any one of claims 1-~~6870~~, wherein the medicament is to be further administered to the subject in combination with ~~further comprising the administration of~~ granulocyte-colony stimulating factor (G-CSF) ~~to the subject~~.

~~7072~~. The ~~usemethod~~ of claim ~~6971~~, wherein the G-CSF is to be administered 1 to 3 days after ~~the administration of~~ the anti-CD30 antibody-drug conjugate.

~~7173~~. The ~~usemethod~~ of claim ~~7169~~ or ~~7072~~, wherein the G-CSF is selected from the group consisting of filgrastim, PEG-filgrastim, lenograstim, and tbo-filgrastim.

~~7274~~. The ~~usemethod~~ of any one of claims 1-~~7473~~, wherein ~~the combinatorial therapy administering the lenalidomide, or salt or solvate thereof, and the antibody drug conjugate that binds to CD30 to the subject~~ results in a depletion of cancer cells by at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% compared to the amount of cancer cells before ~~the combinatorial therapy administering the lenalidomide, or salt or solvate thereof, and/or the antibody drug conjugate that binds to CD30 to the subject~~.

~~7375~~. The ~~usemethod~~ of any one of claims 1-~~7274~~, wherein one or more therapeutic effects in the subject is improved after ~~the combinatorial therapy administration of the lenalidomide, or salt or solvate thereof, and the antibody drug conjugate that binds to CD30~~ relative to a baseline.

~~7476~~. The ~~usemethod~~ of claim ~~7375~~, wherein the one or more therapeutic effects is selected from the group consisting of: objective response rate, duration of response, time to response, progression free survival and overall survival.

~~7577~~. The ~~usemethod~~ of any one of claims 1-~~7476~~, wherein the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%.

~~7678~~. The ~~usemethod~~ of any one of claims 1-~~7577~~, wherein the subject exhibits progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after ~~the combinatorial therapy administration of the lenalidomide, or salt or solvate thereof, and/or the antibody drug conjugate that binds to CD30~~.

~~7779~~. The ~~use~~method of any one of claims 1-~~7678~~, wherein the subject exhibits overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after the combinatorial therapy administration of the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30.

~~7880~~. The ~~use~~method of any one of claims 1-~~7779~~, wherein the duration of response to the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30 is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after the combinatorial therapy administration of the lenalidomide, or salt or solvate thereof, and/or the antibody-drug conjugate that binds to CD30.

~~7981~~. The ~~use~~method of any one of claims 1-~~7880~~, wherein the subject is a human.

~~8082~~. A pharmaceutical composition for use in the treatment of non-Hodgkin lymphoma in a subject, the composition comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, ~~wherein the composition is for use in a method of any one of claims 1-79~~.

~~8183~~. The pharmaceutical composition of claim ~~80-82~~ further comprising an anti-CD20 antibody or antigen-binding fragment thereof.

~~82~~84. A kit comprising lenalidomide, or salt or solvate thereof, and an antibody-drug conjugate that binds to CD30, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding fragment thereof conjugated to a monomethyl auristatin or a functional analog thereof or a functional derivative thereof, and instructions for using the kit to treat non-Hodgkin lymphoma in a subject~~in the method of any one of claims 1-79~~.

~~83~~85. The kit of claim ~~82-84~~ further comprising an anti-CD20 antibody or antigen-binding fragment thereof.